Table 1.
Dynamics of TP53 mutations in treatment-naïve under ibrutinib and relapsed/refractory patients under ibrutinib and chemoimmunotherapy.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.